US firm's patent bid for TB therapy rejected
A US company's patent bid for a life-saving TB therapy was rejected. A patent gives a firm exclusive rights to an invention, so this decision matters for the drug.
ContextTuberculosis is a bacterial infection that mainly affects the lungs and still causes many deaths each year, with India carrying one of the highest TB burdens globally. Patent rulings can decide whether cheaper generic versions of a drug reach patients.
Read at Times of India: India
Burning Potato score: 48%